Ferring Pharma acquires Rebiotix Inc. and with it microbiome RBX 2660 for Clostridium Difficile infection

Ferring Pharmaceuticals and Rebiotix Inc. announce that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings together two innovative healthcare companies that share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients. The most advanced investigational microbiome treatment from Rebiotix is RBX 2660, a non-antibiotic treatment currently in Phase III development for the prevention of recurrent Clostridium Difficile Infection (CDI). RBX 2660 has the potential to be the first human microbiome product approved anywhere in the world. In the US, RBX 2660 has received FDA Fast Track, Breakthrough Therapy and Orphan Drug Designations, which means the FDA considers it eligible for Expedited Review, once the submission has been made. Rebiotix�s proprietary MRT drug platform delivers healthy, live, human-derived microbes into the gastrointestinal tract. It provides a standardised, stabilised product that is ready-to-use in an easy-to-administer format. The MRT pipeline consists of a number of investigational treatments including RBX 7455, a non-frozen, lyophilised oral capsule formulation, in development for the prevention of recurrent CDI.